Biblio
Export 244 results:
Author Title Type Year Filters: First Letter Of Keyword is I [Clear All Filters]
“Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.”, J Alzheimers Dis, vol. 50, no. 2, pp. 539-46, 2016.
, “Looking for Neuroimaging Markers in Frontotemporal Lobar Degeneration Clinical Trials: A Multi-Voxel Pattern Analysis Study in Granulin Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 249-62, 2016.
, “Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau.”, J Alzheimers Dis, vol. 53, no. 1, pp. 1-14, 2016.
, “Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies.”, J Alzheimers Dis, vol. 76, no. 1, pp. 21-25, 2020.
, “Protective Effect of Amyloid-β Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1227-41, 2016.
, “The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.”, J Alzheimers Dis, vol. 94, no. s1, pp. S45-S66, 2023.
, “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Plasma Biomarkers of Alzheimer's Disease in African Americans.”, J Alzheimers Dis, vol. 79, no. 1, pp. 323-334, 2021.
, “Anti-Inflammatory Gene Therapy Improves Spatial Memory Performance in a Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1001-1008, 2022.
, “Impaired IL-17 Production in Gut-Residing Immune Cells of 5xFAD Mice with Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 61, no. 2, pp. 619-630, 2018.
, “Protective Effect of Amyloid-β Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1227-41, 2016.
, “Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 973-977, 2021.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Anti-Inflammatory Gene Therapy Improves Spatial Memory Performance in a Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1001-1008, 2022.
, “Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1235-1247, 2017.
, “Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1399-1410, 2018.
, “Plasma Biomarkers of Alzheimer's Disease in African Americans.”, J Alzheimers Dis, vol. 79, no. 1, pp. 323-334, 2021.
, “Association of Interleukin-6 and Interleukin-8 with Cognitive Decline in an Asian Memory Clinic Population.”, J Alzheimers Dis, vol. 92, no. 2, pp. 445-455, 2023.
, “Association of Interleukin-6 and Interleukin-8 with Cognitive Decline in an Asian Memory Clinic Population.”, J Alzheimers Dis, vol. 92, no. 2, pp. 445-455, 2023.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1237-47, 2016.
,